Approach to the patient: Long-term management of prolactinomas

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 8, 2007, Pages 2861-2865

  Schlechte, Janet A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; ESTROGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; AMENORRHEA; ARTICLE; CASE REPORT; DRUG EFFICACY; FEMALE; FEMALE FERTILITY; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; MALE; MICROADENOMA; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; TREATMENT OUTCOME; TUMOR VOLUME; HYPOPHYSIS TUMOR; MENOPAUSE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; PREGNANCY; REVIEW;

ADULT; AMENORRHEA; CONTRACEPTIVES, ORAL, HORMONAL; DOPAMINE AGONISTS; ESTROGENS; FEMALE; GALACTORRHEA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENOPAUSE; MIDDLE AGED; PITUITARY NEOPLASMS; PREGNANCY; PROLACTINOMA;

EID: 34547806222     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0836     Document Type: Article

References (46)

1. Schlechte JA 2003 Prolactinoma. N Engl J Med 349:2035-2041
2. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Change RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO 1985 Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698-705
3. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MR 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904-909
4. Colao A, Di Sarno A, Sarnacchiaro S, Ferone D, DiRenzo G, Merola B, Annunziato L, Lombardi G 1997 Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82:876-883
5. Gillam MP, Molitch ME, Lombardi G, Colao A 2006 Advances in the treatment of prolactinomas. Endocr Rev 27:485-534
6. Schlechte J, Dolan K, Sherman B, Chaplet F, Luciano A 1989 The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412-418
7. Weiss MH, Teal J, Gott P, Wycoff R, Yadley R, Apuzzo ML, Giannotta SL, Kletzky O, March C 1983 Natural history of microprolactinomas: six-year follow-up. Neurosurgery 12:180-183
8. Sano T, Kovacs KT, Scheithauer BW, Young Jr WF 1993 Aging and the human pituitary gland. Mayo Clin Proc 68:971
9. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J 1997 Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102-2107
10. Molitch ME 1985 Pregnancy and the hyperprolactinemic woman. N Engl J Med 312:1365-1370
11. Holmgren U, Hagenfeldt K, Werner S 1986 Women with prolactinomas: effect of pregnancy and lactation on serum prolactin and on tumour growth. Acta Endocrinol (Copenh) 111:452-459
12. Krupp P, Monka C 1987 Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65:823-827
13. Robert E, Musatti L, Piscitelli G, Ferrari CI 1996 Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10:333-337
14. Corenblum B, Donovan L 1993 The safety of physiological estrogen plus progestin replacement therapy with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 59:671-673
15. Scheithauer BW, Kovacs KT, Randall RV, Ryan N 1992 Effects of estrogen on the human pituitary: a clinicopathologic study. Mayo Clin Proc 64:1077-1084
16. Pituitary Adenoma Study Group 1983 Pituitary adenomas and oral contraceptives: a multicenter case-control study. Fertil Steril 39:753-760
17. Fathy UM, Foster PA, Torode HW, Hartog M, Hull MG 1992 The effect of combined estrogen/progesterone treatment in women with hyperprolactinemic amenorrhea. Gynecol Endocrinol 6:183-188
18. Testra G, Vegetti W, Motta T, Alagna F, Bianchedi D, Carlucci C, Bianchi M, Parazzini F, Crosignani PG 1998 Two year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 58:69-73
19. Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J 1996 Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 45:299-303
20. Crosignani PG, Mattei AM, Scarduelli C, Cavioni V, Boracchi P 1989 Is pregnancy the best treatment for hyperprolactinaemia? Hum Reprod 4:910-912
21. Freeman R, Wezenter B, Silverstein M, Kuo D, Weiss KL, Kantrowitz AB, Schubart UK 1992 Pregnancy-associated subacute hemorrhage into a prolactinoma resulting in diabetes insipidus. Fertil Steril 58:427-429
22. Karunakaran S, Page RC, Wass JA 2001 The effect of menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 54:295-300
23. Landolt AM, Osterwalder V 1984 Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58:1179-1183
24. Johnston DG, Kendall-Taylor P, Watson M, Hall K, Patrick D, Cook DB 1984 Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Lancet 2:187-192
25. Zarate A, Canales ES, Cano C, Pilonieta CJ 1983 Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol (Copenh) 104:139-142
26. Moriondo P, Travaglini P, Nissim M, Conti A, Faglia G 1985 Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60:764-772
27. Wang C, Lam KS, MA JT, Chan T, Liu MY, Yeung RT 1987 Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol (Oxf) 27:363-371
28. Rasmussen C, Bergh T, Wide L 1987 Prolactin secretion and menstrual function after long-term bromocriptine treatment. Fertil Steril 48:550-554
29. Van't Verlaat JW, Croughs RJ 1991 Withdrawal of bromocriptine after longterm therapy for macroadenomas; effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf) 34:175-178
30. Ferrari C, Paracchi A, Mattei A, de Vincentiis S, D'Alberton A, Crosignani P 1992 Cabergoline in long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh) 126:489-494
31. Muratori M, Arosio M, Gambina G, Biella O, Faglia G 1997 Use of cabergoline in the long-term treatment of hyperprolactinaemic and acromegalic patients. J Endocrinol Invest 20:537-546
32. Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F 1999 Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenomas. J Endocrinol Invest 22:354-359
33. Passos VQ, Souza JJ, Musolino NR, Bronstein MD 2002 Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87:3578-3582
34. Colao A, Di Sarno A, Cappabianca P, De Somma C, Pivonello R, Lombardi G 2003 Withdrawal of long-term carbergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023-2033
35. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS 2005 Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63:26-31
36. Guitelman M 2006 Long-term follow-up of prolactimomas: should dopamine agonist treatment be life-long? Front Horm Res 35:88-101
37. Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G 1985 Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313:656-659
38. Jane Jr JA, Laws Jr ER 2001 The surgical management of pituitary adenomas in a series of 2093 patients. J Am Coll Surg 193:651-659
39. Nomikos P, Buchfelder M, Fahlbusch R 2001 Current management of prolactinomas. J Neurooncol 54:139-150
40. Couldwell WT, Rovit RL, Weiss MH 2003 Role of surgery in the treatment of microprolactinomas. Neurosurg Clin North Am 14:89 -92, vii
41. Thompson JA, Davies DL, McLaren EH, Teasdale GM 1994 Ten year follow-up of microprolactinoma treated by transsphenoidal surgery. BMJ 309:409-410
42. Tintner R, Manian P, Gauthier P, Jankovic J 2005 Pleuropulmonary fibrosis after long-term pergolide for Parkinson disease. Arch Neurol 62:1290-1295
43. McElvaney NG, Wilcox PG, Churg A, Fleetham JA 1988 Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 148:2231-2236
44. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46
45. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E 2007 Dopamine agonists and the risk of cardiac valve regurgitation. N Engl J Med 356:29-38
46. Gillam MP, Middler S, Freed DJ, Molitch ME 2002 The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of giant prolactinoma. J Clin Endocrinol Metab 87:4447-4451